Insider buying last 90 days
No open-market insider purchases were filed for IDXX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every IDXX insider filing, plotted on the chart in Gekko.Open IDXX in Gekko
NASDAQ: IDXX
IDEXX Laboratories (IDXX) Stock Analysis & Forecast
$511.65+5.17 (+1.0%)
Close on Sep 18, 2026. Page updated Sep 19, 9:19 pm ET.
Gekko Brief
AI summaryIDXX closes at $511.65, up 1% on the day, but remains below both its 50-day average of $550.94 and its 200-day average of $597.44, with the 50-day itself below the 200-day. Trailing returns show a decline of 9% over one month, 9% over three months, 11.8% over six months and 20.2% over the past year. The GekkoIndex reads 67.4, placing the stock in the Accumulation zone, while Gekko Fair Value stands at $506.56, putting price about 1% above that level.
This week's news centers on IDEXX's acquisition of CoVetAI, a company specializing in AI-native ambient listening and clinical workflow software for veterinary practices, a deal framed as expanding IDEXX's AI-native software capabilities in diagnostics and practice performance; shares rose 0.6% following the announcement. Separately, IDEXX expanded its Faecal Dx antigen testing platform in the United Kingdom to include taeniid tapeworm detection, broadening its intestinal parasite screening offering. The company also presented at the Morgan Stanley 24th Annual Global Healthcare Conference.
Looking ahead, IDEXX's next earnings report is scheduled for 2 November 2026, before the open, 43 days out and beyond a typical 20-trading-day hold; the prior quarter's EPS of $4.27 beat the $3.95 estimate and produced a 3% reaction, with an average absolute reaction of 9.1% across the last eight quarters, all beats. Seasonality from this point has averaged a 20-day return of -4.1% over five years, with 0 of those years positive. Analyst coverage from 7 firms shows 4 buy and 3 hold ratings, with a consensus target of $698.92, implying 36.6% upside from current levels. One billionaire holder and one trailblazer holder are noted; no insider, Congress, or options signal activity appears in their respective windows.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $511.65200-day averageGekko Fair Value $506.56
Key stats
- Market cap
- $40.36B
- P/E ratio
- 36.1
- Forward P/E
- 31.1
- EPS, TTM
- $14.03
- Revenue, TTM
- $4.55B
- Profit margin
- 25%
- Dividend yield
- —
- Beta
- 1.54
- Volume
- 1.12M avg 493,334
- 1-year return
- −20.2%
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±5.1%
- 50-day average
- $550.94
- 200-day average
- $597.44
- Next earnings
- Nov 2 before open
- Shares outstanding
- 78.78M
IDEXX Laboratories swing-trade checklist
IDEXX Laboratories scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $511.65 is below the 50-day ($550.94) and 200-day ($597.44) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
67.4, Accumulation
Reading 67.4 is in the Accumulation zone.
See the GekkoIndex - Fair valuemixed
1.0% above
Price is within 5% of Gekko Fair Value (1% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 43 days
Next report Nov 2, 2026, 43 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−4.1% on average
From this point in the calendar, the next 20 trading days averaged −4.1% over 5 years, rising in 0 of them.
See seasonality
A description of current data, not a recommendation. How this page works
IDEXX Laboratories stock chart and price history
IDEXX Laboratories closed at $511.65 on Sep 18, 2026, −20.2% over the past year, inside a 52-week range of $500.61 to $769.98.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −9.0%
- 3 months
- −9.0%
- 6 months
- −11.8%
- 1 year
- −20.2%
The full IDXX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IDXX in Gekko
Follow IDEXX Laboratories through every session
Put IDXX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track IDXX in GekkoFree for 7 days. No credit card required.
About IDEXX Laboratories
IDEXX Laboratories develops and sells diagnostic products and services used mainly by veterinary practices, along with buyers in livestock, poultry, dairy, and water testing. It is widely recognized for its veterinary diagnostics, including point-of-care instruments, consumables, and rapid assay kits used to test companion animals, alongside laboratory testing and consultation work, imaging tools, and practice management software for clinics.
The business is arranged into groups covering companion animal diagnostics, water quality testing, and livestock, poultry, and dairy health monitoring, with further offerings beyond these core areas. Its water testing line includes tests such as Colilert, Colilert-18, Colisure, Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray, used to check for contaminants like coliforms and E. coli. IDEXX also makes instruments for blood gas and electrolyte analysis, chemistry and hematology testing, and SARS-CoV-2 RT-PCR tests, reaching both veterinary and human diagnostic customers, including independent clinics and larger veterinary groups. Sales run through its own marketing, service, and technical teams, as well as outside distributors and resellers.
Founded in 1983, IDEXX Laboratories is headquartered in Westbrook, Maine, and its shares are listed on the NASDAQ under the ticker IDXX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- idexx.com
IDEXX Laboratories GekkoIndex: the smart money zone
IDEXX Laboratories’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.4, in the Accumulation zone, down 1.3 points over five sessions.
67.4Accumulation
Down 1.3 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 34 | +0.1% | +1.7% | ||
| Accumulation (current zone) | 255 | +0.1% | −0.2% | ||
| Neutral | 337 | +0.1% | +0.4% | ||
| Distribution | 35 | −0.1% | +2.1% | ||
| Selling | 1 | Too few readings yet | |||
Average IDXX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the IDXX price, zone by zone.Track IDXX in Gekko
Is IDEXX Laboratories stock overvalued? Gekko Fair Value
IDEXX Laboratories trades 1.0% above Gekko Fair Value of $506.56, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what IDEXX Laboratories shares are worth, recalculated every trading day.
$506.56
Gekko Fair Value, Sep 19, 2026
1.0% above fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open IDXX in Gekko
IDEXX Laboratories insider and Congress trading
No open-market insider purchases were filed for IDEXX Laboratories, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in IDXX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for IDXX, plotted on the chart in Gekko.Open IDXX in Gekko
Buybacks
IDEXX Laboratories has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $346.8M
- As a share of market cap
- 0.86%
- Trailing four quarters
- $1.18B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold IDXX.
0added1opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
IDEXX Laboratories earnings: next date and track record
IDEXX Laboratories reports on Nov 2, 2026, before the open (43 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Nov 2, 2026
Expected before the open, 43 days away
- EPS estimate
- $3.71
- Revenue estimate
- $1.19B
8 of 8reports beat the EPS estimate
±9.1%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- IDEXX reported an excellent Q2 2026 with revenue up ~10% reported and 9% organic, driven by strong recurring CAG Diagnostics growth, double-digit international growth, robust Water and LPD performance, and continued momentum in instrument placements (inVue Dx). Management highlighted gross margin expansion, comparable operating margin improvement of 110 basis points, and EPS of $4.27 (15% comparable EPS growth). Key commercial drivers include inVue Dx rollout and FNA controlled launch, multi-cancer Cancer Dx adoption, strong reference lab conversions, and international commercial investments. Management raised full-year revenue guidance modestly and reiterated continued investments in commercial expansion, R&D, and IT/AI. They emphasized high customer retention (high 90s) and confidence in long-term sector development despite modest headwinds in U.S. same-store clinical visits and some macro/FX impacts.
- Guidance
- Updated full-year 2026 revenue range: $4,700M to $4,745M (midpoint increased ~$5M net); overall organic revenue growth outlook: 8.5%–9.7%; organic CAG Diagnostics recurring revenue growth: 9.5%–10.7%. Full-year inVue Dx placement goal ~5,500 units (year-to-date ~2,700). Q3 comparable operating margin expected to benefit 20–50 bps. Management noted a $15M headwind from updated foreign currency effects and a $20M operational performance increase netting to the midpoint change. No explicit multi-year financial targets beyond these updates were provided on the call.
- Risks flagged
- U.S. same-store clinical visits declined ~1.3% in the quarter and wellness visits remain pressured (down ~3%); macroeconomic headwinds (consumer inflationary pressures, gas and housing costs) can constrain discretionary spend; FX headwind (~$15M) to 2026 outlook; continued investment spending may pressure near-term margins; competitive pressures in reference lab market (though management cites conversions); forward-looking statements subject to customary risks and uncertainties.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $4.27 est $3.95 | $1.22B est $1.20B | +3.0% |
| May 5, 2026 | $3.47 est $3.41 | $1.14B est $1.12B | +2.9% |
| Feb 2, 2026 | $3.08 est $2.94 | $1.09B est $1.07B | −5.7% |
| Nov 3, 2025 | $3.40 est $3.14 | $1.11B est $1.07B | +14.7% |
| Aug 4, 2025 | $3.63 est $3.28 | $1.11B est $1.06B | +19.9% |
| May 1, 2025 | $2.96 est $2.85 | $998.4M est $997.1M | +9.1% |
| Feb 3, 2025 | $2.62 est $2.39 | $954.3M est $935.1M | +10.2% |
| Oct 31, 2024 | $2.80 est $2.68 | $975.5M est $980.3M | −7.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
IDEXX Laboratories stock forecast and analyst price targets
Analysts’ average 12-month price target for IDEXX Laboratories is $698.92, +36.6% from the last close, from 7 firms rating the stock in the last 90 days.
$698.92consensus 12-month target, +36.6% from the last close
Now $511.65Avg $698.92
Low $665High $805
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 16 | UBS | $670 | +30.9% |
| Aug 14 | Bank of America Securities | $665 | +30.0% |
| Aug 14 | Stifel Nicolaus | $675 | +31.9% |
| Aug 13 | William Blair | — | — |
| Aug 11 | Barclays | $710 | +38.8% |
−0.2%average 20-day move after past Accumulation readings
−4.1%average move over the next 20 trading days in the last 5 years
±2.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
IDEXX Laboratories seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, IDEXX Laboratories averaged −4.1% across the last 5 years, rising in 0 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.1% | 0 of 5 |
| Next 10 trading days | −4.7% | 0 of 5 |
| Next 15 trading days | −5.2% | 0 of 5 |
| Next 20 trading days | −4.1% | 0 of 5 |
| Next 30 trading days | −4.3% | 2 of 5 |
For scale, IDXX’s typical 20-trading-day move in either direction is about 5.1%.
IDEXX Laboratories market cap and key statistics
IDEXX Laboratories’s market cap is $40.36B, with a P/E ratio of 36.1 and revenue of $4.55B over the last twelve months.
Valuation
- Market cap
- $40.36B
- P/E ratio
- 36.1
- Forward P/E
- 31.1
- EPS, TTM
- $14.03
- Gekko Fair Value
- $506.56
Trading
- Volume
- 1.12M
- Avg volume, 20 days
- 493,334
- 52-week high
- $769.98
- 52-week low
- $500.61
- Shares outstanding
- 78.78M
Financials
- Revenue, TTM
- $4.55B
- Profit margin
- 25%
- Return on equity
- 74.2%
- Quarterly earnings growth, YoY
- +17.6%
Risk and income
- Beta
- 1.54
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±5.1%
IDEXX Laboratories stock news this week
6 headlines about IDEXX Laboratories from the past week, newest first, each linking to the publisher.
- IDEXX Stock Gains Following the Acquisition of CoVetZacks Investment Research, Sep 17
- IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm DetectionBusiness Wire, Sep 17
- IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow IntelligenceYahoo Finance, Sep 16
- Press Release: IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow IntelligenceMoomoo, Sep 16
- IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha, Sep 14
- Financial Analysis: IDEXX Laboratories (NASDAQ:IDXX) vs. InMode (NASDAQ:INMD)Defense World, Sep 11
IDEXX Laboratories peers
IDEXX Laboratories’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 17.1% above |
| ABTAbbott Laboratories | Accumulation | 15.5% below |
| DHRDanaher | Neutral | 1.1% above |
| ISRGIntuitive Surgical | Neutral | 12.3% above |
| MDTMedtronic | Neutral | 24.7% below |
| SYKStryker | Buying | 17.1% below |
A peer links to its own page where one exists.
IDEXX Laboratories stock FAQ
What is IDEXX Laboratories’s market cap?
IDEXX Laboratories’s market cap is $40.36B at the Sep 18, 2026 close of $511.65, with 78.78M shares outstanding. The shares trade on a P/E ratio of 36.1.
What is the IDEXX Laboratories stock forecast?
The consensus analyst 12-month price target for IDEXX Laboratories is $698.92, +36.6% from the last close. Of the 7 firms that rated the stock in the last 90 days, 4 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is IDEXX Laboratories stock overvalued or undervalued?
On Gekko’s estimate IDEXX Laboratories is about fair value: the Sep 18, 2026 close of $511.65 is 1.0% above Gekko Fair Value of $506.56. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does IDEXX Laboratories report earnings next?
IDEXX Laboratories is expected to report on Nov 2, 2026, before the market opens (43 days away). Analysts expect earnings of $3.71 per share on revenue of $1.19B. IDEXX Laboratories beat the earnings estimate in 8 of its last 8 reports, moving 9.1% on average across the report.
What is IDEXX Laboratories’s 52-week high and low?
IDEXX Laboratories’s 52-week high is $769.98 and its 52-week low is $500.61; it closed at $511.65 on Sep 18, 2026, −20.2% over the past year.
Is IDEXX Laboratories stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and earnings risk), 1 as mixed (fair value) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See IDEXX Laboratories the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.